The Preferred First-Line Device Therapy for BPH
Developing a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that rapidly restores urinary function and allows patients an early return to normal, daily life.
The FloStentTM System
Adam Kadlec, MD is the President and CEO of Rivermark Medical. In addition to being an experienced innovator, Adam is a board-certified Urologist with expertise in various forms of minimally invasive surgery. He received his undergraduate and medical degrees at the University of Wisconsin-Madison and completed a Residency and Fellowship in Urology at Loyola University Medical Center in Chicago.
Andy Doraiswamy serves as Rivermark Medical’s Chairman and Board Director. An established executive and entrepreneur, Andy brings over a decade of experience commercializing next-generation medical technologies, most recently as Founding CEO of Koya Medical. He received his Ph.D. in Biomedical Engineering from the School of Medicine at the University of North Carolina-Chapel Hill, an M.S. in Materials Science & Engineering from the University of Arizona, and a B.S. in Chemical Engineering from the University of Madras.
Andy Schieber is Head of Engineering at Rivermark Medical. Andy is a medical device engineer with 20 years of experience designing novel medical technologies. He is the Owner and Principal of Ingenarious Consultants, a design-build medtech firm in Orange County California. Andy received an M.S. in Mechanical Engineering at the University of Minnesota-Twin Cities and a B.S. in Engineering from the University of Wisconsin-Stout.